Extraction (chemistry)

Koch Modular to Expand State-of-the-Art Pilot Plant in Houston, Texas

Retrieved on: 
Tuesday, March 26, 2024
Research, Other Energy, Energy, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Other Manufacturing, Science, Engineering, Chemicals, Plastics, Manufacturing, Other Science, Flavor, Conference, Medication, Distillation, Extraction (chemistry), Neste, CST

Koch Modular Process Systems (Koch Modular), a market-leading provider of engineered and fabricated modular mass transfer systems for the chemical processing industry, announces the expansion of its Houston, TX pilot plant.

Key Points: 
  • Koch Modular Process Systems (Koch Modular), a market-leading provider of engineered and fabricated modular mass transfer systems for the chemical processing industry, announces the expansion of its Houston, TX pilot plant.
  • The expanded and well-equipped Koch Modular pilot plant enables companies to run both bench and pilot-scale tests to generate data required to develop and test mass transfer processes.
  • “Rolling this expansion out this year means a lot to our team because 2024 marks our twenty-fifth year of Engineered Innovation as an organization when our company became Koch Modular Process Systems,” said Tom Lightfoot , Pilot Plant Manager at Koch Modular.
  • To learn more about pilot plant testing, Tom Schafer , Vice President of Koch Modular, will be presenting at the AIChE Conference in New Orleans, LA , on March 27 at 4:30 pm CST on the topic of “Modular Pilot & Demonstration Scale-Plants: A Cornerstone for Accelerating the Global Transition to Clean Energy.” As an exhibitor, Koch Modular looks forward to networking opportunities and sharing its expertise on pilot plant testing within the chemical processing industry.

Waters Streamlines and Expedites PFAS Testing with Innovative Oasis Dual-Phase Cartridges

Retrieved on: 
Thursday, March 14, 2024
QC, Comment, GCB, PFAS, Phosphatidylethanolamine, Environment, WAT, Filtration, Risk, European Chemicals Agency, WAX, Carbon, Centrifugation, Workflow, Laboratory, EPA, Waters Corporation, Compensation, Safe Drinking Water Act, Biosolids, Soil, CERCLA, Extraction (chemistry), Cosmetics

MILFORD, Mass., March 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announces new Oasis WAX/GCB and GCB/WAX for PFAS Analysis Cartridges with new design features that significantly streamline and expedite sample preparation and analysis of per- and polyfluoroalkyl substances (PFAS). To help ensure accuracy and further confidence in test results, Oasis WAX/GCB and GCB/WAX Cartridges are QC-tested by an accredited laboratory for low residual PFAS, to reduce or eliminate any time spent troubleshooting potential assay contamination.

Key Points: 
  • Waters Oasis™ Dual-phase PFAS Analysis Cartridges simplify sample preparation for EPA 1633 testing for analysis of PFAS concentrations in non-potable water, soils, biosolids, and tissue.
  • MILFORD, Mass., March 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announces new Oasis WAX/GCB and GCB/WAX for PFAS Analysis Cartridges with new design features that significantly streamline and expedite sample preparation and analysis of per- and polyfluoroalkyl substances (PFAS).
  • Oasis WAX/GCB & GCB/WAX Cartridges are the latest products within Waters extensive portfolio of PFAS testing solutions.
  • Oasis WAX/GCB and GCB/WAX Cartridges are the latest products within a comprehensive portfolio of PFAS Testing Solutions offered by Waters to support the surging demand for PFAS environmental testing.

Waters Streamlines and Expedites PFAS Testing with Innovative Oasis Dual-Phase Cartridges

Retrieved on: 
Thursday, March 14, 2024
QC, Comment, GCB, PFAS, Phosphatidylethanolamine, Environment, WAT, Filtration, Risk, European Chemicals Agency, WAX, Carbon, Centrifugation, Workflow, Laboratory, EPA, Waters Corporation, Compensation, Safe Drinking Water Act, Biosolids, Soil, CERCLA, Extraction (chemistry), Cosmetics

MILFORD, Mass., March 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announces new Oasis WAX/GCB and GCB/WAX for PFAS Analysis Cartridges with new design features that significantly streamline and expedite sample preparation and analysis of per- and polyfluoroalkyl substances (PFAS). To help ensure accuracy and further confidence in test results, Oasis WAX/GCB and GCB/WAX Cartridges are QC-tested by an accredited laboratory for low residual PFAS, to reduce or eliminate any time spent troubleshooting potential assay contamination.

Key Points: 
  • Waters Oasis™ Dual-phase PFAS Analysis Cartridges simplify sample preparation for EPA 1633 testing for analysis of PFAS concentrations in non-potable water, soils, biosolids, and tissue.
  • Cartridge lots are QC-tested by an accredited laboratory for low residual PFAS to help reduce or eliminate time spent troubleshooting PFAS contamination.
  • MILFORD, Mass., March 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announces new Oasis WAX/GCB and GCB/WAX for PFAS Analysis Cartridges with new design features that significantly streamline and expedite sample preparation and analysis of per- and polyfluoroalkyl substances (PFAS).
  • Oasis WAX/GCB and GCB/WAX Cartridges are the latest products within a comprehensive portfolio of PFAS Testing Solutions offered by Waters to support the surging demand for PFAS environmental testing.

RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use and Addiction with TETRANITE®

Retrieved on: 
Wednesday, October 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Dental, Clinical Trials, Science, Biotechnology, Medical Supplies, FDA, Other Science, Health, NIDCR, Extraction (chemistry), MMSc, Alveolar osteitis, SBIR, Doctor of Philosophy, United, Multimedia, OUD, Tissue, Phase II, DRS, Tooth, NIH, United States drug overdose death rates and totals over time, Initiative, DMD, Regenerative medicine, Pain management, Addiction, Pain, Patient, Diagnosis, Bangladesh Technical Education Board, Pharmaceutical industry, Dentistry, Medical device

This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.

Key Points: 
  • This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.
  • This grant will fund the pre-clinical development of a dental bone graft formulation that will include the release of locally acting non-opioid pain medication.
  • Opioid use disorder (OUD) is a major problem in the US, accounting for 107,622 overdose deaths in 2021.
  • This also expands upon a Phase II SBIR grant ( 1R44DE032564-01 ) which RevBio received from the National Institute of Dental and Cranial Research (NIDCR).

Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™ SPE Workflow and Kits

Retrieved on: 
Thursday, October 19, 2023
Acceleration, Science, FDA, NYSE, Therapy, Extraction (chemistry), LC-MS, Oligonucleotide, ChromeOS, Metabolism, Drug development, Contract research organization, SPE, Workflow, Laboratory, Kits, WAT, MS, Waters Corporation, Fine chemical, Pharmaceutical industry

MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x[i] increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

Key Points: 
  • MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides.
  • The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline.
  • Our new OligoWorks SPE Kits directly address oligonucleotide bioanalysis sample prep challenges across diverse oligo therapeutics," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation.
  • Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis.

Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™ SPE Workflow and Kits

Retrieved on: 
Thursday, October 19, 2023
Acceleration, Science, FDA, NYSE, Therapy, Extraction (chemistry), LC-MS, Oligonucleotide, ChromeOS, Metabolism, Drug development, Contract research organization, SPE, Workflow, Laboratory, Kits, WAT, MS, Waters Corporation, Fine chemical, Pharmaceutical industry

MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x[i] increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

Key Points: 
  • MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides.
  • The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline.
  • Our new OligoWorks SPE Kits directly address oligonucleotide bioanalysis sample prep challenges across diverse oligo therapeutics," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation.
  • Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis.

Almost Half of Adults Age 30 and Older Suffer from Gum Disease

Retrieved on: 
Thursday, September 28, 2023
Slate, Extraction (chemistry), Plaque, Tooth enamel, Osteoporosis, Macdonald, CDC, Patient, Risk, Periodontal disease, Ageing, Bacteria, News, Tongue, Dentistry, Nightclub, Tile

SPOKANE, Wash., Sept. 28, 2023 /PRNewswire/ -- Unlike many of us, Jared MacDonald, 34, loves going to the dentist. However, until recently, each check-up brought bad news.

Key Points: 
  • SPOKANE, Wash., Sept. 28, 2023 /PRNewswire/ -- Unlike many of us, Jared MacDonald, 34, loves going to the dentist.
  • "They told me if I didn't start flossing, it could lead to bone loss and surgery."
  • A recent CDC report says 47.2% of adults aged 30 years and older have some form of periodontal disease.
  • Warning signs of periodontal disease include:
    Receding gums are cause for concern because they expose tooth enamel and put more areas at risk of decay.

Church & Dwight Issues National Recall of One Specific Lot of TheraBreath Strawberry Splash for Kids 16oz Sold Exclusively on Amazon Between May 31 and September 02, 2023, due to microbial contamination identified as yeast (Candida parapsilosis).

Retrieved on: 
Wednesday, September 13, 2023
Online, Fungemia, Extraction (chemistry), Completeness, Fungal infection, Universal Product Code, Infection, Lot, UPC, TheraBreath (brand), Church & Dwight, Knowledge, Candida parapsilosis, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Vaccine, Dietary supplement, Amazon

No other TheraBreath products or other lots of TheraBreath Strawberry Splash for Kids are included in this recall.

Key Points: 
  • No other TheraBreath products or other lots of TheraBreath Strawberry Splash for Kids are included in this recall.
  • The use of the affected product in immune compromised individuals could potentially result in severe or life-threatening adverse events such as fungemia or disseminated fungal infection.
  • TheraBreath Strawberry Splash for Kids is indicated as an anti-cavity mouthwash for adults and children 6 years of age and older.
  • The lot of recalled mouthwash product is listed below with the Universal Product Code (UPC) and Lot number.

Abra Health Expands Dental Services with Acquisition of Two Prominent Oral Surgery Practices in Northern New Jersey

Retrieved on: 
Wednesday, August 2, 2023
General Health, Health, Dental, Practice Management, Extraction (chemistry), Patient satisfaction, Dental implant, Multimedia, Name, Acquisition, DMD, Patient, DDS, Oral and maxillofacial surgery, Dental care, Oral, Dentistry

Abra Health, a leading provider of comprehensive dental care, is excited to announce the acquisition of two oral surgery practices in the Northern New Jersey area.

Key Points: 
  • Abra Health, a leading provider of comprehensive dental care, is excited to announce the acquisition of two oral surgery practices in the Northern New Jersey area.
  • The practices, known as Bayonne Oral Surgery in Bayonne, NJ, and Oral & Maxillofacial Surgery Institute in Newark, NJ, will join forces under the new umbrella of the Abra Health group called Garden State Oral Surgery Group.
  • "We are thrilled to welcome Bayonne Oral Surgery and Oral & Maxillofacial Surgery Institute to the Abra Health family," said Dr. Michael Skolnick, DMD, CEO of Abra Health.
  • For more information about Garden State Oral Surgery Group and the expanded dental services now available, please visit the new website at gardenstateos.com.

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product

Retrieved on: 
Wednesday, June 7, 2023
Health, Medical Devices, Dental, Clinical Trials, Research, Science, Biotechnology, Maintenance, Extraction (chemistry), Surgeon, University, Osteoporosis, Tooth, SBIR, University of Pennsylvania School of Dental Medicine, Porosity, Multimedia, Doctor of Philosophy, Bangladesh Technical Education Board, Regenerative medicine, National Institute of Dental and Craniofacial Research, Membrane, DMD, Patient, NIDCR, Engineering, Dentistry, IDE, FDA, All India Mahila Congress, NIH, Safety

This funding ( 1R44DE032564-01 ) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.

Key Points: 
  • This funding ( 1R44DE032564-01 ) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
  • These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases.
  • These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed.
  • This product compliments RevBio’s existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.